Post-market results mirror trial data for Boston Scientific’s Watchman
A review of the 1st 1,000 patients implanted with Boston Scientific‘s (NYSE:BSX) Watchman device showed similar results as in clinical trials of the anti-stroke implant.
The implant success rate was 97%, comparable to that observed in the pre-approval clinical trials, with the remaining patients showing an average residual jet size of 2.3mm.
That consistency “makes you think that the procedure is ready for prime time, that it’s a good procedure with good results,” Dr. Kenneth Ellenbogen of Richmond’s Virginia Commonwealth University, speaking on behalf of the American Heart Assn., told TCTMD. “I don’t think there are going to be any big surprises.” Read more